🟢 Novavax is trading 11% up today as biotech shares rebound after Moderna results

Novavax is trading at $10.81, up 10.58%, as biotech-sector momentum appears to support the November 6 rebound.

• Third-quarter revenue beat estimates; management raised its 2026 adjusted revenue outlook to $385–$415 million, including a $125 million Sanofi milestone.
• The profitability target was pushed to 2029; Reuters reported this overshadowed the outlook increase, and shares fell 9% on November 5.
• The rebound appears supported by stronger biotech sentiment after Moderna’s results; XBI was up 2.01%. This points more to sector momentum than a new Novavax-specific announcement.